MARKET

EXEL

EXEL

Exelixis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.72
+0.18
+0.88%
After Hours: 20.96 +0.24 +1.16% 19:59 09/17 EDT
OPEN
20.45
PREV CLOSE
20.54
HIGH
20.75
LOW
19.96
VOLUME
3.94M
TURNOVER
--
52 WEEK HIGH
27.19
52 WEEK LOW
16.19
MARKET CAP
6.53B
P/E (TTM)
72.02
1D
5D
1M
3M
1Y
5Y
Exelixis Announces U.S. FDA Approval Of CABOMETYX (cabozantinib) For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older
Benzinga · 14h ago
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
ALAMEDA, Calif., September 17, 2021--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older with locally ...
Business Wire · 14h ago
Exelixis Gets FDA's Approval for Cabometyx to Treat Thyroid Cancer -- Stock Up 3% After-Hours
MT Newswires · 18h ago
Fuller & Thaler Behavioral Small-mid Core Equity Buys Pool Corp, Science Applications ...
GuruFocus News · 1d ago
Fuller & Thaler Behavioral Unconstrained Equity Buys Dollar General Corp, Capital One ...
GuruFocus News · 1d ago
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
Benzinga · 1d ago
Exelixis Announces CABOMETYX(R) in Combination with OPDIVO(R) Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced results demonstrating efficacy benefits regardless of prior nephrectomy status with CABOMETYX(R) (cabozantinib) in combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab) versus sunitinib for patients wit...
Business Wire · 2d ago
Exelixis Statement on the Passing of Two Senior Executives
ALAMEDA, Calif., September 06, 2021--Exelixis, Inc. (Nasdaq: EXEL) today announced that Gisela M. Schwab, M.D., the company’s President, Product Development and Medical Affairs and Chief Medical Officer, passed away over the weekend. Dr. Schwab had been on...
Business Wire · 09/06 17:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXEL. Analyze the recent business situations of Exelixis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXEL stock price target is 31.77 with a high estimate of 65.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 508
Institutional Holdings: 288.55M
% Owned: 91.59%
Shares Outstanding: 315.05M
TypeInstitutionsShares
Increased
116
17.83M
New
39
1.62M
Decreased
120
11.62M
Sold Out
43
1.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Stelios Papadopoulos
Chief Executive Officer/President/Director
Michael Morrissey
Chief Financial Officer/Executive Vice President
Christopher Senner
Executive Vice President/Chief Scientific Officer
Peter Lamb
Executive Vice President/General Counsel
Jeffrey Hessekiel
Executive Vice President
Patrick Haley
Independent Director
Charles Cohen
Independent Director
Carl Feldbaum
Independent Director
Maria Freire
Independent Director
Alan Garber
Independent Director
Vincent Marchesi
Independent Director
George Poste
Independent Director
Julie Smith
Independent Director
Lance Willsey
Independent Director
Jack Wyszomierski
No Data
About EXEL
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.